Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-870-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.25 million
Profitability
Miscellaneous
Employees79
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) posted its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.03. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
2 brokers have issued 12 month price objectives for Calithera Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Calithera Biosciences' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 99.5% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Has Calithera Biosciences been receiving favorable news coverage?
Media stories about CALA stock have been trending negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Calithera Biosciences earned a news impact score of -2.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Calithera Biosciences.
Are investors shorting Calithera Biosciences?
Calithera Biosciences saw a increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,084,500 shares, an increase of 18.7% from the June 15th total of 913,300 shares. Based on an average daily trading volume, of 377,300 shares, the days-to-cover ratio is currently 2.9 days. Approximately 3.3% of the shares of the stock are sold short. View Calithera Biosciences' Current Options Chain.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include Spectrum Pharmaceuticals (SPPI), ZIOPHARM Oncology (ZIOP), ANI Pharmaceuticals (ANIP), Vanda Pharmaceuticals (VNDA), Kura Oncology (KURA), Axsome Therapeutics (AXSM), Arvinas (ARVN), OrganiGram (OGI), Alder Biopharmaceuticals (ALDR), Eagle Pharmaceuticals (EGRX), CannTrust (CNTTF), Akero Therapeutics (AKRO), Cytokinetics (CYTK), Retrophin (RTRX) and Amneal Pharmaceuticals (AMRX).
What other stocks do shareholders of Calithera Biosciences own?
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
- Dr. Keith Orford, Chief Medical Officer (Age 47)
- Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.23%), Vanguard Group Inc. (5.39%), Point72 Asset Management L.P. (4.93%), CVI Holdings LLC (1.57%), Renaissance Technologies LLC (1.91%) and Sofinnova Investments Inc. (1.35%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Keith Orford and Susan Molineaux. View Institutional Ownership Trends for Calithera Biosciences.
Which major investors are selling Calithera Biosciences stock?
Which major investors are buying Calithera Biosciences stock?
CALA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., CVI Holdings LLC, Sofinnova Investments Inc., Vanguard Group Inc., Monashee Investment Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC and BlackRock Inc.. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $4.01.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $215.62 million and generates $22.25 million in revenue each year. The biotechnology company earns $-54,630,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe.View Additional Information About Calithera Biosciences.
What is Calithera Biosciences' official website?
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
